Dose Insider / Glossary / FDA drug shortage list

FDA drug shortage listWhat it is and why it mattered for GLP-1s

Updated November 20, 2026 · 4 min read · FDA drug shortages page 2026; FDA compounding statements 2024-2026

The FDA drug shortage list, kept in FDA's Drug Shortage Database, records drugs whose supply in the United States does not meet demand, along with resolved shortages and discontinued products.

90 daysTirzepatide, 503B outsourcing facilities, grace period after the shortage
Grace period after the shortageDays FDA gave compounders to stopTIRZEPATIDE503A pharmacies61 days503B outsourcing facilities90 daysSEMAGLUTIDE503A pharmacies60 days503B outsourcing facilities90 daysGrace period after theshortageDays FDA gave compounders to stopTIRZEPATIDE503A pharmacies61 days503B outsourcing facilities90 daysSEMAGLUTIDE503A pharmacies60 days503B outsourcing facilities90 days

The 503A dates could run longer if a court ruled later.

On this page

A shortage listed as current means FDA is aware of the supply problem and is working with the makers to ease it. For GLP-1 medicines the list mattered more than for most drugs: while semaglutide and tirzepatide were on it, federal law let compounders make copies of them.1,2

How the list works

FDA says shortages happen for many reasons, including manufacturing and quality problems, delays and discontinuations. Manufacturers provide most of the shortage information, and FDA works closely with them to prevent shortages or reduce their impact. Drug makers can notify FDA's Drug Shortage Staff of new problems through a dedicated portal.1

Patients and health care providers can take part too. FDA asks people who cannot find a medicine to first search the database by the generic name or active ingredient. If the drug is listed, it suggests talking with a health care provider or pharmacist about other options during the shortage. If it is not listed, they can report a new shortage through a public portal. FDA notes that a drug missing from one pharmacy is usually a temporary, local problem, but that local reports can signal a national shortage and help it act early.1

FDA's other shortage tools

The database sits beside other FDA resources. FDA keeps a list of extended use dates to stretch supplies during shortages, sends Congress an annual report on its actions, the latest covering 2025, and published a 2019 report on the causes of shortages and possible solutions. The CARES Act of 2020 widened its power to identify, prevent and ease shortages.1 For the GLP-1 medicines, FDA set out its policy in a running statement, "FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize", with entries from December 2024 to April 2026.3

Why the list matters for compounding

The list is written into the compounding law. An outsourcing facility under section 503B may compound from a bulk drug substance only in two cases. One is to make a drug that is on FDA's shortage list at the time of compounding, distribution and dispensing; the other is when the substance is on the 503B bulks list.4 For a 503A pharmacy, a shortage changes whether a compounded product counts as a copy of an approved drug.2

The GLP-1 shortages and their end

During the shortages, pharmacies and outsourcing facilities made what were in effect copies of Wegovy, Ozempic, Zepbound and Mounjaro.2 Then the shortages ended:3

For 503A pharmacies, FDA said the date would run longer if a court ruled later in a lawsuit brought by outsourcing facilities.3

Since then, outsourcing facilities may not use bulk semaglutide, which is on neither the shortage list nor the 503B bulks list, and on April 30, 2026 FDA proposed to exclude semaglutide, tirzepatide and liraglutide from that bulks list.5

FDA has kept counting problems with the products made in that period and since. By May 31, 2026 it had received 990 adverse event reports about compounded semaglutide and more than 730 about compounded tirzepatide.2

What it means today

A claim that a compounded GLP-1 is legal "because of the shortage" is out of date: the shortages are over, and a quick search of the database by active ingredient shows their status at any time. The makers now also sell the approved products directly, with self-pay prices from $299 a month for Zepbound and $149 for the Wegovy tablet on the makers' own pages.6 Our page on compounded semaglutide explains what FDA still allows, and GLP-1 costs without insurance compares the approved options.

Sources

  1. U.S. Food and Drug Administration. Drug shortages. Content current as of July 15, 2026, read November 20, 2026. fda.gov
  2. U.S. Food and Drug Administration. FDA's concerns with unapproved GLP-1 drugs used for weight loss. Content current as of October 1, 2026. fda.gov
  3. U.S. Food and Drug Administration. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize. Entries of December 19, 2024 to April 1, 2026. fda.gov
  4. U.S. Food and Drug Administration. Bulk drug substances used in compounding. Content current as of March 26, 2026, read November 20, 2026. fda.gov
  5. U.S. Food and Drug Administration. FDA proposes to exclude semaglutide, tirzepatide, and liraglutide on 503B bulks list. Press announcement, April 30, 2026. fda.gov
  6. Dose Insider. GLP-1 cost without insurance: every self-pay price compared. Prices read November 20, 2026, from the makers' self-pay pages. doseinsider.com

Related analyses

Log each fill and where it came from, so supply gaps never become dose gaps.

Open Dose Insider